| Chanh M Tu, MD | |
|
1119 E Lamar St, Americus, GA 31709-3762 | |
| (229) 924-4022 | |
| (229) 924-7133 |
| Full Name | Chanh M Tu |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 32 Years |
| Location | 1119 E Lamar St, Americus, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134198765 | NPI | - | NPPES |
| 000720178E | Medicaid | GA | |
| 00720178A | Medicaid | GA | |
| 000720178D | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 042468 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Phoebe Sumter Medical Center | Americus, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regional Eye Center, Llp | 1557350121 | 6 |
News Archive
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.
The disease familial combined hyperlipidemia (FCH) is a common cause of disturbed metabolism of fat and early heart attacks.
Researchers at Johns Hopkins Medicine say they have added to evidence that rapid resistance gene sequencing technology can accurately speed the identification of specific antibiotic-resistant bacteria strains that sicken and kill some patients.
While a fever is one of the most common symptoms for people who get sick with COVID-19, taking one's temperature is a poor means of screening who is infected with the SARS-CoV-2 virus that causes the disease, and more importantly, who might be contagious.
Université Laval's Infectious Disease Research Centre and Centre de recherche du CHU de Québec-Université Laval are proud to announce that the first clinical study for a Zika vaccine in Canada is set to begin in Quebec City.
› Verified 2 days ago
| Entity Name | Regional Eye Center, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790836864 PECOS PAC ID: 1557350121 Enrollment ID: O20040510000089 |
News Archive
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.
The disease familial combined hyperlipidemia (FCH) is a common cause of disturbed metabolism of fat and early heart attacks.
Researchers at Johns Hopkins Medicine say they have added to evidence that rapid resistance gene sequencing technology can accurately speed the identification of specific antibiotic-resistant bacteria strains that sicken and kill some patients.
While a fever is one of the most common symptoms for people who get sick with COVID-19, taking one's temperature is a poor means of screening who is infected with the SARS-CoV-2 virus that causes the disease, and more importantly, who might be contagious.
Université Laval's Infectious Disease Research Centre and Centre de recherche du CHU de Québec-Université Laval are proud to announce that the first clinical study for a Zika vaccine in Canada is set to begin in Quebec City.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chanh M Tu, MD 1119 E Lamar St, P O Box 788, Americus, GA 31709-3762 Ph: (229) 924-4022 | Chanh M Tu, MD 1119 E Lamar St, Americus, GA 31709-3762 Ph: (229) 924-4022 |
News Archive
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.
The disease familial combined hyperlipidemia (FCH) is a common cause of disturbed metabolism of fat and early heart attacks.
Researchers at Johns Hopkins Medicine say they have added to evidence that rapid resistance gene sequencing technology can accurately speed the identification of specific antibiotic-resistant bacteria strains that sicken and kill some patients.
While a fever is one of the most common symptoms for people who get sick with COVID-19, taking one's temperature is a poor means of screening who is infected with the SARS-CoV-2 virus that causes the disease, and more importantly, who might be contagious.
Université Laval's Infectious Disease Research Centre and Centre de recherche du CHU de Québec-Université Laval are proud to announce that the first clinical study for a Zika vaccine in Canada is set to begin in Quebec City.
› Verified 2 days ago